A carregar...
Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to reduce hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the reduction varies between patients and adequate glycemic control may not be achieved. We evaluated the efficacy and safety of the DPP-4 inhibitor alogliptin...
Na minha lista:
| Publicado no: | J Clin Med Res |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elmer Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4701069/ https://ncbi.nlm.nih.gov/pubmed/26767082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2418w |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|